ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Sulfasalazine

Also written as “Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Arthritis, Juvenile · Arthritis, Rheumatoid, led by 2 companies.

Drug pageSulfasalazine: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 11, 20204 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only20 open or runningphase 1since Feb 11, 2020Feb 11, 2020none ahead
Pfizer20 open or runningphase 4since Jan 11, 2007Jan 11, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 11, 2007First study: phase 4 study in Arthritis, RheumatoidFirst studyNCT00422227 · 300 enrolled · Hong Kong, India, Korea, Republic of and more
  2. Mar 11, 2008Phase 4 study in Arthritis, JuvenileNCT00637780 · 2 enrolled · United States, Mexico

TargetBeta

“Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule

Studies

All 2 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00637780Arthritis, Juvenile · United States, Mexico4TerminatedJan 20142
NCT00422227Arthritis, Rheumatoid · Hong Kong, India, Korea, Republic of and more4CompletedMar 2009300

How it is read

Names in the registry

  • “Sulfasalazine”, 6 entries
  • “Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.